What is the efficacy of ombitasvir/paritaprevir/ritonavir (Technivie) for the treatment of hepatitis C (Hep C) infection?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print

Ombitasvir/paritaprevir/ritonavir (Technivie)

Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin was studied in treatment-naïve and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I). [126] In previously untreated patients, SVR12 rates were 100% (42/42) in the ribavirin-containing regimen and 90.9% (40/44) in the ribavirin-free regimen. All treatment-experienced patients achieved SVR12 (49/49). In the ribavirin-free group, 2 of 42 (5%) treatment-naïve patients had virologic relapse, and 1 of 44 (2%) had virologic breakthrough; no virologic failures were recorded in the ribavirin-containing regimen. [126]

The combination product ombitasvir/paritaprevir/ritonavir (Technivie) was FDA approved in July 2015 for the treatment of genotype 4 chronic HCV without cirrhosis. [127] It is recommended to be used in conjunction with ribavirin.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!